Jan Mattsson - BioArctic S Fin
| BIOA-B Stock | SEK 228.00 10.40 4.36% |
Insider
Jan Mattsson is S Fin of BioArctic AB
| Age | 63 |
| Phone | 46 86 95 69 30 |
| Web | https://www.bioarctic.se |
BioArctic Management Efficiency
BioArctic's management efficiency ratios could be used to measure how well BioArctic manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Mustafa Demirbker | XSpray Pharma AB | N/A | |
| Krassimir Mitchev | Calliditas Therapeutics | 64 | |
| AnnKristin BSc | Calliditas Therapeutics | 68 | |
| MSc MD | Oncopeptides AB | N/A | |
| Peter Nygren | Oncopeptides AB | 64 | |
| Marie Svensson | Alligator Bioscience AB | 59 | |
| Jonathan Schur | Calliditas Therapeutics | 70 | |
| Malin Carlsson | Alligator Bioscience AB | 55 | |
| Julie Silber | Alligator Bioscience AB | N/A | |
| Fredrik Johansson | Calliditas Therapeutics | 46 | |
| Linda Holmstrom | Oncopeptides AB | N/A | |
| Sren Bregenholt | Alligator Bioscience AB | 52 | |
| AnnaKarin Ekberg | XSpray Pharma AB | 57 | |
| Sumeet MD | Alligator Bioscience AB | N/A | |
| Mikael Widell | Calliditas Therapeutics | 65 | |
| Per Andersson | XSpray Pharma AB | 56 | |
| Andreas Konar | XSpray Pharma AB | 74 | |
| Annika MBA | Oncopeptides AB | 57 | |
| Jakob Lic | Oncopeptides AB | 51 | |
| Pr MD | Oncopeptides AB | N/A | |
| Renee AguiarLucander | Calliditas Therapeutics | 61 | |
Management Performance
| Return On Equity | -0.0142 | |||
| Return On Asset | -0.0055 |
BioArctic AB Leadership Team
Elected by the shareholders, the BioArctic's board of directors comprises two types of representatives: BioArctic inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BioArctic. The board's role is to monitor BioArctic's management team and ensure that shareholders' interests are well served. BioArctic's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, BioArctic's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Gunilla Andersson, Director HR | ||
| Pr Gellerfors, Sr CoFounder | ||
| Jan Mattsson, S Fin | ||
| Christer Mller, VP Officer | ||
| Gunilla Osswald, Chief Officer | ||
| Pr Lannfelt, VP CoFounder | ||
| Oskar Bosson, VP IR | ||
| Frida Lekander, Head Marketing | ||
| Johanna Flting, VP Research | ||
| Harald Borgeke, Head Affairs |
BioArctic Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is BioArctic a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0142 | |||
| Return On Asset | -0.0055 | |||
| Profit Margin | (0.05) % | |||
| Operating Margin | (0.03) % | |||
| Current Valuation | 26.19 B | |||
| Shares Outstanding | 73.73 M | |||
| Shares Owned By Insiders | 48.40 % | |||
| Shares Owned By Institutions | 30.39 % | |||
| Price To Earning | 12.95 X | |||
| Price To Book | 32.29 X |
Pair Trading with BioArctic
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if BioArctic position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in BioArctic will appreciate offsetting losses from the drop in the long position's value.Moving together with BioArctic Stock
| 0.73 | VITR | Vitrolife AB | PairCorr |
| 0.7 | GENO | Genovis AB | PairCorr |
Moving against BioArctic Stock
| 0.41 | SKA-B | Skanska AB | PairCorr |
The ability to find closely correlated positions to BioArctic could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace BioArctic when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back BioArctic - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling BioArctic AB to buy it.
The correlation of BioArctic is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as BioArctic moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if BioArctic AB moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for BioArctic can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioArctic AB. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Complementary Tools for BioArctic Stock analysis
When running BioArctic's price analysis, check to measure BioArctic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioArctic is operating at the current time. Most of BioArctic's value examination focuses on studying past and present price action to predict the probability of BioArctic's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioArctic's price. Additionally, you may evaluate how the addition of BioArctic to your portfolios can decrease your overall portfolio volatility.
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio |